FAHD2B

Across TCGA pan-cancer cohorts, FAHD2B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAHD2B data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher FAHD2B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAHD2B expression acts as an unfavorable survival marker.

HNSC, LIHC, and COAD are the cancer types where FAHD2B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.078	0.710	<.001	24	view →
LIHC	DFS	Median	All	0.047	0.556	<.001	24	view →
COAD	OS	Median	All	0.172	0.870	<.001	18	view →
ESCA	DFS	Median	II,III,IV	0.166	0.525	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAHD2B–HNSC (DFS)

Open the HNSC breakdown →